thalidomide has been researched along with Chemical and Drug Induced Liver Injury in 21 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n = 11), 8 mg/kg (n = 17), and 10 mg/kg (n = 15)." | 6.79 | A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. ( Chen, WM; Geng, C; Hou, J; Huang, Z; Ke, X; Liu, Y; Qiu, L; Wang, F; Wang, Z; Wei, N; Wei, P; Xi, H; Yang, S; Zhao, Y; Zheng, X; Zhu, B, 2014) |
| " Thalidomide is nowadays used for the treatment of several conditions including multiple myeloma (MM)." | 4.88 | Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. ( Gonçalves, R; Lopes, J; Macedo, G; Sobrinho Simões, M; Vilas-Boas, F, 2012) |
| "Thalidomide is a relatively safe and efficacious form of therapy in the treatment of advanced, refractory multiple myeloma." | 3.73 | Thalidomide-induced severe hepatotoxicity. ( Hanje, AJ; Meis, GM; Shamp, JL; Thomas, FB, 2006) |
| " A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n = 11), 8 mg/kg (n = 17), and 10 mg/kg (n = 15)." | 2.79 | A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. ( Chen, WM; Geng, C; Hou, J; Huang, Z; Ke, X; Liu, Y; Qiu, L; Wang, F; Wang, Z; Wei, N; Wei, P; Xi, H; Yang, S; Zhao, Y; Zheng, X; Zhu, B, 2014) |
| "Lenalidomide is an immunomodulatory drug frequently used for treatment of patients with multiple myeloma and myelodysplastic syndromes." | 2.48 | Lenalidomide-associated hepatotoxicity--a case report and literature review. ( Fontana, RJ; Konda, A; Nojkov, B; Signori, C, 2012) |
| "Lenalidomide has been shown to be potentially teratogenic in thalidomide-sensitive animal species." | 1.48 | Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA. ( Guengerich, FP; Kamiya, Y; Kusama, T; Mitsui, M; Murayama, N; Shimizu, M; Suemizu, H; Uehara, S; Yamazaki, H, 2018) |
| "Thalidomide has recently enjoyed renewed interest as a treatment in many disorders, including plasma cell leukemia." | 1.31 | Thalidomide-associated hepatitis: a case report. ( Fowler, R; Imrie, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 2 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Kenna, JG | 1 |
| Stahl, S | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Chen, M | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Schmutz, JL | 1 |
| Murayama, N | 1 |
| Suemizu, H | 1 |
| Uehara, S | 1 |
| Kusama, T | 1 |
| Mitsui, M | 1 |
| Kamiya, Y | 1 |
| Shimizu, M | 1 |
| Guengerich, FP | 1 |
| Yamazaki, H | 1 |
| Reed-Guy, L | 1 |
| Hoteit, MA | 1 |
| Garfall, AL | 1 |
| Tokuyama, M | 1 |
| Shimizu, T | 1 |
| Yamada, T | 1 |
| Kondoh, A | 1 |
| Mabuchi, T | 1 |
| Veluswamy, RR | 1 |
| Ward, SC | 1 |
| Yum, K | 1 |
| Abramovitz, RB | 1 |
| Isola, LM | 1 |
| Jagannath, S | 1 |
| Parekh, S | 2 |
| Geng, C | 1 |
| Hou, J | 1 |
| Zhao, Y | 1 |
| Ke, X | 1 |
| Wang, Z | 1 |
| Qiu, L | 1 |
| Xi, H | 1 |
| Wang, F | 1 |
| Wei, N | 1 |
| Liu, Y | 1 |
| Yang, S | 1 |
| Wei, P | 1 |
| Zheng, X | 1 |
| Huang, Z | 1 |
| Zhu, B | 1 |
| Chen, WM | 1 |
| Levesque, E | 1 |
| Bradette, M | 1 |
| Dabak, V | 1 |
| Kuriakose, P | 1 |
| Vilas-Boas, F | 1 |
| Gonçalves, R | 1 |
| Sobrinho Simões, M | 1 |
| Lopes, J | 1 |
| Macedo, G | 1 |
| Nojkov, B | 1 |
| Signori, C | 1 |
| Konda, A | 1 |
| Fontana, RJ | 1 |
| Trojan, A | 1 |
| Chasse, E | 1 |
| Gay, B | 1 |
| Pichert, G | 1 |
| Taverna, C | 1 |
| HEINE, W | 2 |
| KIRCHMAIR, H | 2 |
| FIEDLER, M | 1 |
| STUEWE, W | 1 |
| Hanje, AJ | 1 |
| Shamp, JL | 1 |
| Thomas, FB | 1 |
| Meis, GM | 1 |
| Hussain, S | 1 |
| Browne, R | 1 |
| Chen, J | 1 |
| Stüwe, W | 1 |
| Fowler, R | 1 |
| Imrie, K | 1 |
3 reviews available for thalidomide and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induc | 2012 |
Lenalidomide-associated hepatotoxicity--a case report and literature review.
Topics: Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Humans; Lenalidomide; Male; Tha | 2012 |
1 trial available for thalidomide and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 2014 |
17 other studies available for thalidomide and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
[Apremilast withdrawals more frequent in standard practice than in clinical trials].
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Depression; Female; Humans; Male; | 2018 |
Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA.
Topics: Animals; Biomarkers; Chemical and Drug Induced Liver Injury; Humans; Lenalidomide; Liver; Mice; Mode | 2018 |
Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Humans; Liver Failure, Acute; Liver F | 2018 |
Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment.
Topics: Aged; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Creatinine; Electrocardiography; | 2019 |
Adverse drug reaction: pomalidomide-induced liver injury.
Topics: Chemical and Drug Induced Liver Injury; Humans; Male; Middle Aged; Multiple Myeloma; Stem Cell Trans | 2014 |
Hepatotoxicity as a rare but serious side effect of thalidomide.
Topics: Adult; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Diseases | 2009 |
Thalidomide-induced severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Fatal Outcome; Female; Humans; | 2009 |
Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Immunosuppressive Agents; Liver; Middle Aged | 2003 |
[THALIDOMIDE EMBRYOPATHY IN RABBITS FOLLOWING TRANSIENT LIVER DAMAGE IN THE MOTHER BY CARBON TETRACHLORIDE].
Topics: Abnormalities, Drug-Induced; Animals; Carbon Tetrachloride; Carbon Tetrachloride Poisoning; Chemical | 1964 |
Thalidomide-induced severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Biopsy; Chemical and Drug Induced Liver Injury; Dexamethasone; Female; | 2006 |
Lenalidomide-induced severe hepatotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Drug Resista | 2007 |
[Thalidomide embryopathy in animal experiments. II. Thalidomide blood level in experimental animals with normal and damaged liver].
Topics: Abnormalities, Drug-Induced; Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Live | 1966 |
Thalidomide-associated hepatitis: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liv | 2001 |
[Malformation and liver damage. On the necessary 2nd noxa in experimental thalidomide embryopathies].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Carbon Tetrachloride; Chemical and Dr | 1967 |